Financial Perspectives’s Biogen BIIB Stock Holding History

Financial Perspectives’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8	Closed	-$2.07K	–	677
2023 Q4	$2.07K	Hold	8	–	–	﹤0.01%	591
2023 Q3	$2.06K	Hold	8	–	–	﹤0.01%	591
2023 Q2	$2.28K	Hold	8	–	–	﹤0.01%	572
2023 Q1	$2.22K	Hold	8	–	–	﹤0.01%	571
2022 Q4	$2.21K	Hold	8	–	–	﹤0.01%	576
2022 Q3	$2.14K	Hold	8	–	–	﹤0.01%	576
2022 Q2	$1.63K	Hold	8	–	–	﹤0.01%	604
2022 Q1	$1.69K	Hold	8	–	–	﹤0.01%	621
2021 Q4	$1.92K	Hold	8	–	–	﹤0.01%	585
2021 Q3	$2.26K	Hold	8	–	–	﹤0.01%	579
2021 Q2	$2.77K	Hold	8	–	–	﹤0.01%	585
2021 Q1	$2.24K	Hold	8	–	–	﹤0.01%	570
2020 Q4	$1.96K	Hold	8	–	–	﹤0.01%	541
2020 Q3	$2.27K	Hold	8	–	–	﹤0.01%	490
2020 Q2	$2.14K	Hold	8	–	–	﹤0.01%	483
2020 Q1	$2.53K	Hold	8	–	–	﹤0.01%	440
2019 Q4	$2.37K	Buy	+8	New	+$2.22K	﹤0.01%	445

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Financial Perspectives's BIIB Position: Q1 2024 in Review

Financial Perspectives sold out of Biogen (BIIB) in Q1 2024, closing a stake of 8 shares — an estimated $2.07K sold.

Financial Perspectives first reported a position in BIIB in Q4 2019 and held it in 17 quarters. The position peaked at $2.77K in Q2 2021. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Financial Perspectives reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Financial Perspectives sold 8 Biogen shares in Q1 2024, an estimated $2.07K.
Financial Perspectives first reported a position in Biogen in Q4 2019 and held it in 17 quarters.
Financial Perspectives's Biogen position peaked at $2.77K in Q2 2021.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Financial Perspectives's 13F filing for Q1 2024, filed 19 Apr 2024.